title: CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
abstract: The bone marrow microenvironment plays a decisive role in multiple myeloma progression and drug resistance. Chemokines are soluble mediators of cell migration, proliferation and survival and essentially modulate tumor progression and drug resistance. Here we investigated bone marrow-derived chemokines of naive and therapy-refractory myeloma patients and discovered that high levels of the chemokine CCL27, known so far for its role in skin inflammatory processes, correlated with worse overall survival of the patients. In addition, chemokine levels were significantly higher in samples from patients who became refractory to bortezomib at first line treatment compared to resistance at later treatment lines.In vitro as well as in an in vivo model we could show that CCL27 triggers bortezomib-resistance of myeloma cells. This effect was strictly dependent on the expression of the respective receptor, CCR10, on stroma cells and involved the modulation of IL-10 expression, activation of myeloma survival pathways, and modulation of proteasomal activity. Drug resistance could be totally reversed by blocking CCR10 by siRNA as well as blocking IL-10 and its receptor.From our data we suggest that blocking the CCR10/CCL27/IL-10 myeloma-stroma crosstalk is a novel therapeutic target that could be especially relevant in early refractory myeloma patients.
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Shanmugapriya
authors.initials: S
authors.lastname: Thangavadivel
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Claudia
authors.initials: C
authors.lastname: Zelle-Rieser
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Angelika
authors.initials: A
authors.lastname: Olivier
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Benno
authors.initials: B
authors.lastname: Postert
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.|Laboratory of Tumor Angiogenesis and Tumorbiology, Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: Gerold
authors.initials: G
authors.lastname: Untergasser
authors.affiliation: Laboratory of Tumor Angiogenesis and Tumorbiology, Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: Johann
authors.initials: J
authors.lastname: Kern
authors.affiliation: Department of Pathology, Medical University Innsbruck, Innsbruck, Austria.
authors.forename: Andrea
authors.initials: A
authors.lastname: Brunner
authors.affiliation: Laboratory of Tumor Angiogenesis and Tumorbiology, Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: Eberhard
authors.initials: E
authors.lastname: Gunsilius
authors.affiliation: Department of Orthopedic Surgery, Medical University Innsbruck, Innsbruck, Austria.
authors.forename: Rainer
authors.initials: R
authors.lastname: Biedermann
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.|Department of Hematooncology, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.|Department of Hematooncology, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
authors.forename: Ludek
authors.initials: L
authors.lastname: Pour
authors.affiliation: Department of Internal Medicine V, University Hospital Innsbruck, Innsbruck, Austria.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Willenbacher
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.|Salzburg Cancer Research Institute-Laboratory of Immunological and Molecular Cancer Research, Salzburg, Austria.|Third Medical Department at The Paracelsus Medical University Salzburg, Austria.|Cancer Cluster Salzburg (CCS), Salzburg, Austria.
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Karin
authors.initials: K
authors.lastname: Jöhrer
mesh_terms: D000368:Aged; D017209:Apoptosis / Q000187:drug effects; D000069286:Bortezomib / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D054425:Chemokine CCL27 / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D034622:RNA Interference; D020239:Receptor Cross-Talk / Q000187:drug effects*; D054447:Receptors, CCR10 / Q000235:genetics / Q000378:metabolism*; D053701:Receptors, Interleukin-10 / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D014162:Transfection; D059016:Tumor Microenvironment; D023041:Xenograft Model Antitumor Assays
chemical_list: C492276:CCL27 protein, human; C515706:CCR10 protein, human; D054425:Chemokine CCL27; C508609:IL10 protein, human; D061988:Proteasome Inhibitors; D054447:Receptors, CCR10; D053701:Receptors, Interleukin-10; D016753:Interleukin-10; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex
keywords: CCL27; CCR10; drug resistance; myeloma; stroma cells